Zhaofeng Niu

Neoadjuvant Pertuzumab Biosimilar HLX11 Versus Reference Pertuzumab for Early-stage or Locally Advanced Breast Cancer: A phase 3 Equivalence Trial

Jin Zhang, Jinhai Zhu, Yaping Yang, Dong Song et autres

cn (code pays fourni par la source)

Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial

Jiayu Wang, Quchang Ouyang, Weimin Xie, Zhaofeng Niu et autres

cn (code pays fourni par la source)

Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial

Herui Yao, Qingyuan Zhang, Huiping Li, Yongmei Yin et autres

cn, us (code pays fourni par la source)

Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial

Yongmei Yin, Qingyuan Zhang, Tao Sun, Chunfang Hao et autres

cn (code pays fourni par la source)

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial

Huiping Li, Jieqiong Liu, Quchang Ouyang, Shusen Wang et autres

cn (code pays fourni par la source)

Abstract PS8-06: A randomized, open-label phase III study comparing disitamab vedotin (an anti-HER2 monoclonal antibody-MMAE conjugate) with lapatinib plus capecitabine in patients with HER2-positive, advanced breast cancer with liver metastasis

Jiayu Wang, Quchang Ouyang, Weimin Xie, Zhaofeng Niu et autres

Abstract P5-07-19: A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in Human Epidermal Growth Factor Receptor 2 positive (HER2+) early breast cancer (EBC) in China: NER-Tree study—An interim analysis on safety

Jin Zhang, Haiguang Liu, Xinlan Liu, Jidong Gao et autres

Bioequivalence of two doxorubicin liposome formulations (LY01612 and Caelyx) using free and encapsulated doxorubicin concentrations in Chinese patients with advanced breast cancer

Lina Zhang, Cuizhi Geng, Mingxia Wang, Wenyan Chen et autres

Pyrotinib in the first-line treatment of HER2-positive advanced breast cancer: Results from the PRETTY study.

Yiqun Li, Zhongsheng Tong, Xinhong Wu, Quchang Ouyang et autres

cn (code pays fourni par la source)

Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China

Benlong Yang, Zhengkui Sun, Quchang Ouyang, Zhongsheng Tong et autres

cn (code pays fourni par la source)

Abstract CT099: BRIGHT-2 final analysis: A phase III trial of bireociclib plus fulvestrant as second-line endocrine therapy for patients with advanced HR+/HER2-breast cancer

Jiayu Wang, Qingyuan Zhang, Huiping Li, Zhongsheng Tong et autres

cn (code pays fourni par la source)

[Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex® for patients with premenopausal breast cancer].

Xinyu Shao, Qinxin Zhang, Zhaofeng Niu, M. LI et autres

cn (code pays fourni par la source)